Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.

Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts. Helicos BioSciences Corporation (Helicos) is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Helicos has developed a technology, called the True Single Molecule Sequencing (tSMS) technology, to facilitate the rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA). The Company's Helicos Genetic Analysis Platform obtains sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. It consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies.

Savient Pharmaceuticals, Inc. company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey. Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers.

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications.In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

Ben Venue Laboratories prides itself on having products that are clean, clear, and cold. A subsidiary of German drug firm Boehringer Ingelheim, the company provides contract manufacturing services, including product and process development and regulatory compliance services. The company specializes in manufacturing liquid and lyophilized (freeze-dried) pharmaceuticals. Ben Venue's Bedford Laboratories division provides contract manufacturing of generic injectable pharmaceuticals. Customers include multinational drugmakers, small biotech development firms, and government agencies.

BioMarin Pharmaceutical Inc. company was founded in 1996 and is headquartered in Novato, California. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase.Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation.

Merz may be a little sterile, but it aims to take care of every part of the functioning human organism. Merz primarily makes pharmaceuticals, focusing on therapies for central nervous system and liver metabolism. The company also offers several OTC products, including cold remedies, skin care products, and vitamin supplements under the brand names tetesept and Merz Special. Subsidiaries include Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, maker of dental equipment and artificial teeth, and Merz & Krell, which produces Senator-brand writing instruments.

Soft Gel Technologies, Inc. company makes hermetically sealed gelatin encapsulations of dietary supplements -- vitamins, minerals, fatty acids, and herbal extracts. The company manufactures more than 150 products, both private label and branded, to promote digestive health, immune system support, urinary tract wellness, and weight loss. Its brands include Carnisol, Femalgen, GlucoFit, and LyCoQ. Soft Gel Technologies also provides contract research and development, formulation, manufacturing, and sales and marketing services for other nutritional products companies. Soft Gel company is owned by Japanese chemicals firm Kenko.

Synbiotics is concerned with the conditions of cats, cows, canines, and other critters. The company provides diagnostic products for the animal health care industry worldwide, through facilities in the US and France. Its canine reproduction services division trains vets in canine reproductive services, including artificial insemination, and runs the Canine Freezing Center Network, which operates what Synbiotics says is the largest bank of frozen canine semen in the world. Synbiotics company also develops and markets test kits for animal parasites, pregnancy, viruses, and other diseases and conditions in the animal kingdom. Its test for bird flu, the FluDetect Avian Influenza Type A antigen kit, is sold globally.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.